Nonalcoholic fatty liver disease: pathology and pathogenesis.

Nonalcoholic fatty liver disease (NAFLD) is recognized as the leading cause of chronic liver disease in adults and children. NAFLD encompasses a spectrum of liver injuries ranging from steatosis to steatohepatitis with or without fibrosis. Fibrosis may progress to cirrhosis and complications including hepatocellular carcinoma. Histologic findings represent the complexity of pathophysiology. NAFLD is closely associated with obesity and is most closely linked with insulin resistance; the current Western diet, high in saturated fats and fructose, plays a significant role. There are several mechanisms by which excess triglycerides are acquired and accumulate in hepatocytes. Formation of steatotic droplets may be disordered in NAFLD. Visceral adipose tissue dysfunction in obesity and insulin resistance results in aberrant cytokine expression; many cytokines have a role in liver injury in NAFLD. Cellular stress and immune reactions, as well as the endocannabinoid system, have been implicated in animal models and in some human studies.

[1]  E. Brunt,et al.  Nonalcoholic fatty liver disease. , 2010, Clinics in liver disease.

[2]  A. Feldstein,et al.  Nonalcoholic steatohepatitis in children: A multicenter clinicopathological study , 2009, Hepatology.

[3]  H. Robenek,et al.  Compartmentalization of proteins in lipid droplet biogenesis. , 2009, Biochimica et biophysica acta.

[4]  L. Ferrucci,et al.  Inflammation and Race and Gender Differences in Computerized Tomography‐measured Adipose Depots , 2009, Obesity.

[5]  K. Isse,et al.  Epithelial–mesenchymal transition induced by biliary innate immunity contributes to the sclerosing cholangiopathy of biliary atresia , 2009, The Journal of pathology.

[6]  Xiaoping Hu,et al.  Quantitative analysis of T2‐correction in single‐voxel magnetic resonance spectroscopy of hepatic lipid fraction , 2009, Journal of magnetic resonance imaging : JMRI.

[7]  V. Paradis,et al.  Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis , 2009, Hepatology.

[8]  A. Dolganiuc,et al.  VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet‐induced nonalcoholic steatohepatitis model in mice , 2009, Hepatology.

[9]  S. Grundy,et al.  Ethnic differences in hepatic steatosis: An insulin resistance paradox? , 2009, Hepatology.

[10]  B. Neuschwander‐Tetri,et al.  Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): A histologic marker of advanced NAFLD—Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network , 2009, Hepatology.

[11]  A. Feldstein,et al.  Hepatic Lipid Partitioning and Liver Damage in Nonalcoholic Fatty Liver Disease , 2009, Journal of Biological Chemistry.

[12]  N. Chalasani,et al.  Nonalcoholic fatty liver disease and cardiovascular risk , 2009, Current gastroenterology reports.

[13]  J. Capeau,et al.  Insulin resistance and steatosis in humans. , 2008, Diabetes & metabolism.

[14]  M. V. Van Natta,et al.  Clinical correlates of histopathology in pediatric nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[15]  A. Diehl,et al.  Mechanisms of disease progression in nonalcoholic fatty liver disease. , 2008, Seminars in liver disease.

[16]  G. Chejfec,et al.  Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? , 2008, Archives of pathology & laboratory medicine.

[17]  M. Yeh,et al.  Animal models of NASH: Getting both pathology and metabolic context right , 2008, Journal of gastroenterology and hepatology.

[18]  Xiong Ma,et al.  Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells. , 2008, Journal of hepatology.

[19]  B. Neuschwander‐Tetri,et al.  Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[20]  Gregory Gores1,et al.  Molecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease , 2008, Seminars in liver disease.

[21]  A. Feldstein,et al.  Diagnosis of Nonalcoholic Fatty Liver Disease: Invasive versus Noninvasive , 2008, Seminars in liver disease.

[22]  B. Roe,et al.  A core gut microbiome in obese and lean twins , 2008, Nature.

[23]  W. Nseir,et al.  Soft drink consumption linked with fatty liver in the absence of traditional risk factors. , 2008, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[24]  G. Godlewski,et al.  Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations. , 2008, Hypertension.

[25]  N. Anderson,et al.  Molecular Mechanisms and Therapeutic Targets in Steatosis and Steatohepatitis , 2008, Pharmacological Reviews.

[26]  R. Xu,et al.  Suspected Nonalcoholic Fatty Liver Disease and Mortality Risk in a Population-Based Cohort Study , 2008, The American Journal of Gastroenterology.

[27]  M. Omary,et al.  The genetic background modulates susceptibility to mouse liver Mallory‐Denk body formation and liver injury , 2008, Hepatology.

[28]  Fritz Schick,et al.  Identification and characterization of metabolically benign obesity in humans. , 2008, Archives of internal medicine.

[29]  S. Bischoff,et al.  Nonalcoholic fatty liver disease in humans is associated with increased plasma endotoxin and plasminogen activator inhibitor 1 concentrations and with fructose intake. , 2008, The Journal of nutrition.

[30]  J. Maher,et al.  Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis , 2008, Hepatology.

[31]  J. Kench,et al.  Visceral fat: A key mediator of steatohepatitis in metabolic liver disease , 2008, Hepatology.

[32]  J. Kimmons,et al.  Dietary fructose consumption among US children and adults: the Third National Health and Nutrition Examination Survey. , 2008, Medscape journal of medicine.

[33]  M. Manco,et al.  Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial , 2008, Hepatology.

[34]  Z. Younossi,et al.  Review article: current management of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis , 2008, Alimentary pharmacology & therapeutics.

[35]  A. Rissanen,et al.  Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study. , 2008, European heart journal.

[36]  S. Friedman,et al.  The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease. , 2008, Gastroenterology.

[37]  D. Mozaffarian,et al.  The perfect storm: obesity, adipocyte dysfunction, and metabolic consequences. , 2008, Clinical chemistry.

[38]  E. Parks,et al.  Dietary sugars stimulate fatty acid synthesis in adults. , 2008, The Journal of nutrition.

[39]  G. Lippi,et al.  NASH Predicts Plasma Inflammatory Biomarkers Independently of Visceral Fat in Men , 2008, Obesity.

[40]  C. McClain,et al.  Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. , 2008, Journal of hepatology.

[41]  J. Sheeder,et al.  Presence of the metabolic syndrome in obese adolescents predicts impaired glucose tolerance and nonalcoholic fatty liver disease. , 2008, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[42]  S. McCall,et al.  Fructose consumption as a risk factor for non-alcoholic fatty liver disease. , 2008, Journal of hepatology.

[43]  A. Baranova,et al.  A Novel Diagnostic Biomarker Panel for Obesity-related Nonalcoholic Steatohepatitis (NASH) , 2008, Obesity surgery.

[44]  Wendy S. Wright,et al.  Fat-specific Protein 27 Regulates Storage of Triacylglycerol* , 2008, Journal of Biological Chemistry.

[45]  C. Day,et al.  Genes and nonalcoholic fatty liver disease , 2008, Current diabetes reports.

[46]  G. Gores,et al.  The lysosomal‐mitochondrial axis in free fatty acid–induced hepatic lipotoxicity , 2008, Hepatology.

[47]  S. Stannard,et al.  Noninvasive assessment of hepatic lipid composition: Advancing understanding and management of fatty liver disorders , 2008, Hepatology.

[48]  B. Antonsson,et al.  Mechanism of mitochondrial glutathione-dependent hepatocellular susceptibility to TNF despite NF-kappaB activation. , 2008, Gastroenterology.

[49]  K. Zatloukal,et al.  Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. , 2008, Journal of hepatology.

[50]  B. S. Mohammed,et al.  Liver, muscle, and adipose tissue insulin action is directly related to intrahepatic triglyceride content in obese subjects. , 2008, Gastroenterology.

[51]  G. Musso,et al.  Should Nonalcoholic Fatty Liver Disease Be Included in the Definition of Metabolic Syndrome? A Cross-Sectional Comparison With Adult Treatment Panel III Criteria in Nonobese Nondiabetic Subjects , 2008, Diabetes Care.

[52]  O. Izaola,et al.  Influence of Insulin Resistance and Adipokines in the Grade of Steatosis of Nonalcoholic Fatty Liver Disease , 2008, Digestive Diseases and Sciences.

[53]  B. Neuschwander‐Tetri,et al.  Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels. , 2008, Archives of internal medicine.

[54]  M. Sherman,et al.  Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study. , 2008, Journal of hepatology.

[55]  A. Baranova,et al.  Adipokines and cytokines in non‐alcoholic fatty liver disease , 2007, Alimentary pharmacology & therapeutics.

[56]  J. Crespo,et al.  Lipopolysaccharide-Binding Protein Plasma Levels and Liver TNF-Alpha Gene Expression in Obese Patients: Evidence for the Potential Role of Endotoxin in the Pathogenesis of Non-Alcoholic Steatohepatitis , 2007, Obesity surgery.

[57]  Tongzheng Liu,et al.  Sensitivity of mice to lipopolysaccharide is increased by a high saturated fat and cholesterol diet , 2007, Journal of Inflammation.

[58]  M. Omary,et al.  Keratins let liver live: Mutations predispose to liver disease and crosslinking generates Mallory‐Denk bodies , 2007, Hepatology.

[59]  P. Clavien,et al.  Omega 3 - Omega 6: What is right for the liver? , 2007, Journal of hepatology.

[60]  B. Neuschwander‐Tetri,et al.  The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis , 2007, Hepatology.

[61]  Jing Ye,et al.  Cideb Regulates Diet-Induced Obesity, Liver Steatosis, and Insulin Sensitivity by Controlling Lipogenesis and Fatty Acid Oxidation , 2007, Diabetes.

[62]  Michelle M Wiest,et al.  A lipidomic analysis of nonalcoholic fatty liver disease , 2007, Hepatology.

[63]  C. McClain,et al.  Palmitic acid induces production of proinflammatory cytokine interleukin‐8 from hepatocytes , 2007, Hepatology.

[64]  James E. Nelson,et al.  HFE C282Y mutations are associated with advanced hepatic fibrosis in Caucasians with nonalcoholic steatohepatitis , 2007, Hepatology.

[65]  J. Schwimmer Definitive diagnosis and assessment of risk for nonalcoholic fatty liver disease in children and adolescents. , 2007, Seminars in liver disease.

[66]  H. Tilg,et al.  Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. , 2007, Gastroenterology.

[67]  K. Zatloukal,et al.  From Mallory to Mallory-Denk bodies: what, how and why? , 2007, Experimental cell research.

[68]  C. McClain,et al.  Good fat/bad fat , 2007, Hepatology.

[69]  S. McCall,et al.  Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis , 2007, Hepatology.

[70]  Hirokazu Takahashi,et al.  Telmisartan, An Angiotensin II Type 1 Receptor Blocker, Controls Progress of Nonalcoholic Steatohepatitis in Rats , 2007, Digestive Diseases and Sciences.

[71]  Philipp E. Scherer,et al.  Visceral Fat Adipokine Secretion Is Associated With Systemic Inflammation in Obese Humans , 2007, Diabetes.

[72]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[73]  C. McClain,et al.  Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition. , 2007, The Journal of nutritional biochemistry.

[74]  E. Roberts,et al.  Non-alcoholic steatohepatitis in children. , 2007, Clinics in liver disease.

[75]  J. Sheeder,et al.  34: Presence of the metabolic syndrome (MS) in obese adolescents predicts impaired glucose tolerance (IGT) and fatty liver disease , 2007 .

[76]  Parvez Hossain,et al.  Obesity and diabetes in the developing world--a growing challenge. , 2007, The New England journal of medicine.

[77]  A. Gerbes,et al.  Role of Kupffer cells in host defense and liver disease , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[78]  F. Schick,et al.  The relationships of plasma adiponectin with a favorable lipid profile, decreased inflammation, and less ectopic fat accumulation depend on adiposity. , 2006, Clinical chemistry.

[79]  Jeffrey B. Schwimmer,et al.  Prevalence of Fatty Liver in Children and Adolescents , 2006, Pediatrics.

[80]  D. Nelson,et al.  Familial aggregation of insulin resistance in first-degree relatives of patients with nonalcoholic fatty liver disease. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[81]  Y. Le Marchand-Brustel,et al.  Increased adipose tissue expression of hepcidin in severe obesity is independent from diabetes and NASH. , 2006, Gastroenterology.

[82]  P. Ciampalini,et al.  NAFLD in children: A prospective clinical‐pathological study and effect of lifestyle advice , 2006, Hepatology.

[83]  Kohjiro Ueki,et al.  Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. , 2006, The Journal of clinical investigation.

[84]  Lisa M Yerian,et al.  In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease , 2006, Hepatology.

[85]  S. Caldwell,et al.  Enlarged Hepatocytes in NAFLD Examined with Osmium Fixation: Does Microsteatosis Underlie Cellular Ballooning in NASH? , 2006, The American Journal of Gastroenterology.

[86]  J. Schölmerich,et al.  Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. , 2006, Journal of molecular endocrinology.

[87]  Robert A Fisher,et al.  Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C , 2006, Hepatology.

[88]  L. Sechi,et al.  Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance. , 2006, The Journal of clinical endocrinology and metabolism.

[89]  S. Harrison New treatments for nonalcoholic fatty liver disease , 2006, Current gastroenterology reports.

[90]  G. Gores,et al.  Apoptosis and necrosis in the liver: A tale of two deaths? , 2006, Hepatology.

[91]  H. Cortez‐Pinto,et al.  Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis , 2006, European journal of gastroenterology & hepatology.

[92]  C. McClain,et al.  Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease. , 2005, The Journal of pediatrics.

[93]  F. Marra,et al.  Review article: the pathogenesis of fibrosis in non‐alcoholic steatohepatitis , 2005, Alimentary pharmacology & therapeutics.

[94]  D. Koop,et al.  Steatohepatitis induced by intragastric overfeeding in mice , 2005, Hepatology.

[95]  M. Laakso,et al.  The CIDEA gene V115F polymorphism is associated with obesity in Swedish subjects. , 2005, Diabetes.

[96]  A. Baranova,et al.  A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease , 2005, Hepatology.

[97]  C. Nievergelt,et al.  Histopathology of pediatric nonalcoholic fatty liver disease , 2005, Hepatology.

[98]  D. Pessayre,et al.  NASH: a mitochondrial disease. , 2005, Journal of hepatology.

[99]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[100]  J. Jessurun,et al.  Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. , 2005, The Journal of clinical investigation.

[101]  M. Manos,et al.  Racial and ethnic distribution of nonalcoholic fatty liver in persons with newly diagnosed chronic liver disease , 2005, Hepatology.

[102]  S. Shoelson,et al.  Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB , 2005, Nature Medicine.

[103]  A. Diehl,et al.  Cytokines and the pathogenesis of non-alcoholic steatohepatitis , 2005, Gut.

[104]  Jonathan C. Cohen,et al.  Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity , 2004, Hepatology.

[105]  A. McCullough,et al.  The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.

[106]  L. Krugner-Higby,et al.  Mitochondria in nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.

[107]  A. Diehl Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. , 2004, Clinics in liver disease.

[108]  D. Befroy,et al.  Mechanism of Hepatic Insulin Resistance in Non-alcoholic Fatty Liver Disease* , 2004, Journal of Biological Chemistry.

[109]  G. Gores,et al.  Free fatty acids promote hepatic lipotoxicity by stimulating TNF‐α expression via a lysosomal pathway , 2004 .

[110]  J. Kench,et al.  Beyond insulin resistance in NASH: TNF‐α or adiponectin? , 2004, Hepatology.

[111]  R. Rodrigo,et al.  Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. , 2004, Clinical science.

[112]  R. Townsend,et al.  Dietary fructose reduces circulating insulin and leptin, attenuates postprandial suppression of ghrelin, and increases triglycerides in women. , 2004, The Journal of clinical endocrinology and metabolism.

[113]  A. Lonardo,et al.  Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver , 2004, Hepatology.

[114]  S. Caldwell,et al.  The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis , 2004, Hepatology.

[115]  K. Mak,et al.  Model of nonalcoholic steatohepatitis. , 2004, The American journal of clinical nutrition.

[116]  L. Burgart,et al.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: Results of a randomized trial , 2004, Hepatology.

[117]  T. Roskams,et al.  Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease , 2004, Hepatology.

[118]  M. Beylot,et al.  Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease. , 2003, Diabetes & metabolism.

[119]  Sheng-Cai Lin,et al.  Cidea-deficient mice have lean phenotype and are resistant to obesity , 2003, Nature Genetics.

[120]  C. McClain,et al.  Cytokines and NASH: A pilot study of the effects of lifestyle modification and vitamin E , 2003, Hepatology.

[121]  James G Kench,et al.  Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C , 2003, Hepatology.

[122]  Yu Wang,et al.  The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. , 2003, The Journal of clinical investigation.

[123]  Christopher J. Lyon,et al.  Minireview: adiposity, inflammation, and atherogenesis. , 2003, Endocrinology.

[124]  G. Gores,et al.  Apoptotic Body Engulfment by a Human Stellate Cell Line Is Profibrogenic , 2003, Laboratory Investigation.

[125]  A. Moser,et al.  Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease , 2003, Hepatology.

[126]  E. Kabagambe,et al.  Adipose tissue biomarkers of fatty acid intake. , 2002, The American journal of clinical nutrition.

[127]  Erick M Remer,et al.  The utility of radiological imaging in nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[128]  J. Lefkowitch,et al.  Kupffer Cell Aggregation and Perivenular Distribution in Steatohepatitis , 2002, Modern Pathology.

[129]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[130]  V. Paradis,et al.  High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis , 2001, Hepatology.

[131]  J. Crespo,et al.  Are there Predictive Factors of Severe Liver Fibrosis in Morbidly Obese Patients with Non-alcoholic Steatohepatitis? , 2001, Obesity surgery.

[132]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.

[133]  J. Lavine Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. , 2000, The Journal of pediatrics.

[134]  K. Zatloukal,et al.  Mallory bodies revisited. , 2000, Journal of hepatology.

[135]  G. Hegedűs [Pathology of alcoholic liver disease]. , 2000, Orvosi hetilap.

[136]  K. Batts,et al.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis , 1999, Hepatology.

[137]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[138]  A. Burt,et al.  Diagnosis and interpretation of steatosis and steatohepatitis. , 1998, Seminars in diagnostic pathology.

[139]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[140]  M. Clemens,et al.  Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[141]  M. Bennett,et al.  Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver , 1995, The Lancet.

[142]  R. Simsolo,et al.  The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. , 1995, The Journal of clinical investigation.

[143]  P. Scheuer,et al.  The pathology of diabetic hepatitis , 1988, The Journal of pathology.

[144]  C. M. Leevy FATTY LIVER: A STUDY OF 270 PATIENTS WITH BIOPSY PROVEN FATTY LIVER AND A REVIEW OF THE LITERATURE , 1962 .

[145]  R. Brůha,et al.  Alcoholic liver disease. , 2012, World journal of hepatology.

[146]  E. Brunt,et al.  CHAPTER 41 – Fatty Liver Disease , 2009 .

[147]  Hui Chen,et al.  Consequences of lipid droplet coat proteins down – regulation in liver cells : Abnormal lipid droplet metabolism and induction of insulin resistance , 2008 .

[148]  S. Friedman Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. , 2008, Physiological reviews.

[149]  P. Schirmacher,et al.  Differential pattern of lipid droplet-associated proteins and de novo perilipin expression in hepatocyte steatogenesis , 2008 .

[150]  H. Cortez‐Pinto,et al.  Non-alcoholic steatohepatitis: from cell biology to clinical practice. , 2006, Journal of hepatology.

[151]  C. Day From fat to inflammation. , 2006, Gastroenterology.

[152]  G. Farrell,et al.  LIVER FAILURE AND LIVER DISEASE Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis , 2006 .

[153]  E. Keeffe,et al.  Chapter Thirty-Six – Alcoholic and nonalcoholic fatty liver disease , 2006 .

[154]  M. Camilo,et al.  Nonalcoholic steatohepatitis , 2005, Digestive Diseases and Sciences.

[155]  S. Sanderson,et al.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.

[156]  H. Minuk,et al.  Metabolic syndrome. , 2005, Journal of insurance medicine.

[157]  S. Locarnini Molecular virology of hepatitis B virus. , 2004, Seminars in liver disease.

[158]  Brian P. Mulhall,et al.  Nonalcoholic steatohepatitis , 2004, Current treatment options in gastroenterology.

[159]  J. Schwarz,et al.  Hepatic de novo lipogenesis in normoinsulinemic and hyperinsulinemic subjects consuming high-fat, low-carbohydrate and low-fat, high-carbohydrate isoenergetic diets. , 2003, The American journal of clinical nutrition.

[160]  D. Pessayre,et al.  Mitochondria in Steatohepatitis , 2001, Seminars in liver disease.

[161]  A. Diehl,et al.  Animal Models of Steatosis , 2001, Seminars in liver disease.

[162]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.